PLCB3 Antibody

What is PLCB3 and what are its primary biological functions?

PLCB3 (phospholipase C, beta 3) is a phosphatidylinositol-specific enzyme that catalyzes the production of critical second messenger molecules, specifically diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). It functions as a key transducer in G protein-coupled receptor (GPCR) signaling pathways, being activated by G(q)/G(11) G alpha proteins downstream of GPCR activation . In neutrophils, PLCB3 participates in phospholipase C-activating signaling pathways by promoting RASGRP4 activation through DAG, contributing to neutrophil functional responses . Additionally, PLCB3 plays a significant role in inflammation, particularly in the context of cystic fibrosis, where it regulates intracellular calcium signaling that amplifies IL-8 expression and release, thus influencing neutrophil recruitment in airways .

How does PLCB3 differ structurally and functionally from other phospholipase C family members?

PLCB3 is a 139 kDa protein (calculated molecular weight) that is observed at approximately 150 kDa in experimental contexts . It contains 1234 amino acids and is characterized by specific domains that enable its interaction with G proteins and phosphatidylinositol substrates. Unlike other PLC family members, PLCB3 is specifically activated by G(q)/G(11) G alpha proteins and contributes to distinct signaling cascades. In the context of inflammatory responses, PLCB3 uniquely potentiates the Toll-like Receptors' signaling cascade, making it a potential molecular target for attenuating excessive neutrophil recruitment without completely abolishing inflammatory responses .

What criteria should I consider when selecting a PLCB3 antibody for my specific research application?

When selecting a PLCB3 antibody, consider these critical factors:

• Experimental application compatibility: Determine if the antibody is validated for your specific application (WB, IHC, ELISA, etc.). For example, antibody 21370-1-AP is validated for Western Blot (1:500-1:1000 dilution), Immunohistochemistry (1:50-1:500 dilution), and ELISA applications .

• Species reactivity: Verify the antibody has been tested with your experimental model organism. The available antibodies show various reactivity profiles:

  • Antibody 21370-1-AP: Tested for human and mouse reactivity

  • pSer1105 antibody (ABIN3182492): Reacts with human, rat, and mouse samples

  • EPR5951 antibody: Primarily validated for human samples

• Target epitope relevance: Select antibodies targeting specific regions or phosphorylation sites relevant to your research. For phosphorylation studies, consider phospho-specific antibodies like those targeting pSer1105 or pSer537 .

• Clonality and host species: Choose between polyclonal, monoclonal, or recombinant antibodies based on your experimental needs. Available options include rabbit polyclonal (21370-1-AP), rabbit polyclonal phospho-specific (ABIN3182492), and rabbit recombinant monoclonal (EPR5951) .

• Validation data: Review available validation data specific to your application to ensure optimal performance.

How should I optimize antibody dilutions for Western blot detection of PLCB3?

Optimizing antibody dilutions for Western blot detection of PLCB3 requires systematic testing:

• Initial dilution range: Begin with the manufacturer's recommended dilution range. For example, with antibody 21370-1-AP, start with 1:500-1:1000 dilution .

• Systematic optimization protocol:

  • Prepare identical Western blot membranes with your samples

  • Test a dilution series (e.g., 1:250, 1:500, 1:1000, 1:2000)

  • Maintain consistent secondary antibody dilutions and exposure times

  • Evaluate signal-to-noise ratio at each dilution

• Cell line considerations: Different cell lines may require different optimizations. PLCB3 antibody 21370-1-AP has been positively detected in MCF-7, A431, COLO 320, HEK-293T, and NIH/3T3 cells .

• Band verification: Confirm proper detection by comparing to the expected molecular weight (observed at approximately 150 kDa for PLCB3) .

• Sample-dependent adjustments: As noted in the product information, PLCB3 antibody performance can be sample-dependent, requiring individual optimization for different experimental systems .

What are the recommended protocols for immunohistochemical detection of PLCB3 in tissue samples?

For optimal immunohistochemical detection of PLCB3 in tissue samples:

• Antigen retrieval: Use TE buffer pH 9.0 (primary recommendation) or citrate buffer pH 6.0 (alternative) for effective antigen retrieval .

• Antibody dilution: Begin with a dilution range of 1:50-1:500 for PLCB3 antibody 21370-1-AP, optimizing based on your specific tissue .

• Tissue validation: Human colon tissue has been positively validated for PLCB3 detection using IHC .

• Protocol specificity: Follow the manufacturer's specific IHC protocol for PLCB3 antibodies. For example, antibody 21370-1-AP has a dedicated downloadable IHC protocol available .

• Signal validation: Include appropriate positive and negative controls. For instance, human colon tissue can serve as a positive control for PLCB3 expression .

• Phospho-specific considerations: When using phospho-specific antibodies like pSer1105, additional optimization may be required to preserve phosphorylation status during tissue processing .

How can I effectively detect phosphorylated forms of PLCB3 in my experimental system?

Detecting phosphorylated forms of PLCB3 requires specialized approaches:

• Phospho-specific antibody selection: Choose antibodies that target specific phosphorylation sites of interest:

  • pSer1105 antibody: Detects PLCB3 only when phosphorylated at Serine 1105

  • pSer537 antibody: Targets the phosphorylated Serine 537 residue

  • pThr236 antibody: Recognizes phosphorylation at Threonine 236

• Phosphatase inhibitor usage: During sample preparation, include phosphatase inhibitors in your lysis buffer to preserve phosphorylation status.

• Validation approach: Confirm specificity by treating samples with phosphatase prior to analysis, which should eliminate signal from phospho-specific antibodies.

• Application optimization: For Western blotting applications, transfer conditions and blocking agents may need to be optimized specifically for phospho-epitopes.

• Signal interpretation: When using phospho-specific antibodies like ABIN3182492, understand that they detect "endogenous levels of PLC β3 protein only when phosphorylated at S1105" .

How is PLCB3 implicated in inflammatory signaling in cystic fibrosis, and how can antibodies help investigate this pathway?

PLCB3 plays a critical role in inflammatory signaling in cystic fibrosis (CF) through several mechanisms:

• Genetic association: A nonsynonymous polymorphism in the PLCB3 gene has been associated with lung disease severity in CF patients homozygous for the F508del mutation .

• Signaling pathway: In bronchial epithelial cells exposed to Pseudomonas aeruginosa, PLCB3 mediates extracellular nucleotide-dependent intracellular calcium signaling, leading to:

  • Activation of protein kinase C alpha and beta

  • Activation of nuclear transcription factor NF-κB p65

  • Potentiation of the Toll-like Receptors' signaling cascade

• Inflammatory amplification: PLCB3 regulates intracellular calcium transients that amplify the expression and release of IL-8, the major chemokine recruiting neutrophils in CF airway lungs .

• Research applications of antibodies:

  • Use total PLCB3 antibodies to track expression levels in different CF models

  • Employ phospho-specific antibodies to monitor activation status of PLCB3 following bacterial exposure

  • Apply antibodies in immunoprecipitation to identify protein interaction partners in the inflammatory cascade

  • Utilize antibodies for tissue localization studies to map PLCB3 distribution in CF versus normal tissues

What experimental approaches can be used to investigate PLCB3's role in G protein-coupled receptor signaling pathways?

To investigate PLCB3's role in G protein-coupled receptor (GPCR) signaling:

• Protein detection and quantification:

  • Use Western blotting with validated PLCB3 antibodies (e.g., 21370-1-AP at 1:500-1:1000 dilution) to measure expression levels

  • Apply phospho-specific antibodies like pSer1105 to monitor activation status following receptor stimulation

• Signaling cascade analysis:

  • Track PLCB3-mediated production of second messengers (DAG and IP3)

  • Monitor downstream calcium signaling using fluorescent calcium indicators

  • Assess PKC activation using phospho-specific PKC antibodies

• Protein interaction studies:

  • Perform co-immunoprecipitation with PLCB3 antibodies to identify binding partners

  • Use proximity ligation assays to visualize PLCB3 interactions with G(q)/G(11) proteins

• Functional modulation:

  • Apply siRNA/shRNA knockdown of PLCB3 combined with antibody detection to confirm specificity

  • Reconstitute with wild-type or mutant PLCB3 and use antibodies to confirm expression

• Subcellular localization:

  • Use immunofluorescence with PLCB3 antibodies to track translocation following GPCR activation

  • Perform subcellular fractionation with Western blot detection to quantify redistribution

What are common issues when using PLCB3 antibodies and how can they be resolved?

Common issues with PLCB3 antibodies and their solutions include:

• Weak or absent signal:

  • Increase antibody concentration (start with manufacturer's recommendation, e.g., 1:500-1:1000 for WB)

  • Optimize antigen retrieval methods (for IHC, try both TE buffer pH 9.0 and citrate buffer pH 6.0)

  • Extend incubation time or adjust temperature

  • Check protein extraction efficiency and loading amount

• High background:

  • Increase washing steps

  • Use more stringent blocking conditions

  • Further dilute primary antibody

  • Test alternative blocking agents

• Non-specific bands:

  • Verify expected molecular weight (PLCB3 should appear at approximately 150 kDa)

  • Use positive control lysates from validated cell lines (MCF-7, A431, COLO 320, HEK-293T, NIH/3T3)

  • Consider using more specific monoclonal antibodies

• Variability between experiments:

  • Standardize sample preparation protocols

  • Store antibody according to manufacturer recommendations (e.g., -20°C, with aliquoting unnecessary for this storage temperature)

  • Use consistent exposure times for detection

• Issues with phospho-specific antibodies:

  • Include phosphatase inhibitors in lysis buffers

  • Minimize sample processing time

  • Validate with phosphatase treatment controls

How can I validate the specificity of my PLCB3 antibody?

To validate PLCB3 antibody specificity:

• Positive controls:

  • Use lysates from cell lines known to express PLCB3 (MCF-7, A431, COLO 320, HEK-293T, NIH/3T3)

  • Include recombinant PLCB3 protein as a standard

• Genetic validation:

  • Compare detection in wild-type versus PLCB3 knockdown/knockout samples

  • Perform antibody detection following siRNA-mediated depletion of PLCB3

• Peptide competition:

  • Pre-incubate antibody with the immunizing peptide (when available) to block specific binding

  • For phospho-specific antibodies, use both phosphorylated and non-phosphorylated peptides

• Cross-reactivity assessment:

  • Test reactivity in samples from various species based on the antibody's reported reactivity (human, mouse, rat)

  • Check for detection of related PLC family members

• Multiple antibody validation:

  • Compare results using antibodies targeting different epitopes (e.g., C-terminal versus N-terminal)

  • Verify results with antibodies from different suppliers or different clones

How can PLCB3 antibodies be employed to study intracellular calcium signaling in inflammatory responses?

PLCB3 antibodies can be valuable tools for studying calcium signaling in inflammation:

• Expression correlation studies:

  • Use Western blotting with PLCB3 antibodies to correlate expression levels with calcium signaling intensity

  • Apply immunohistochemistry to map PLCB3 distribution in tissues with active inflammatory responses

• Activation monitoring:

  • Employ phospho-specific antibodies (pSer1105, pSer537, pThr236) to track PLCB3 activation status during inflammation

  • Correlate phosphorylation with calcium transients measured by calcium indicators

• Signaling complex visualization:

  • Use immunofluorescence co-localization to track PLCB3 association with calcium signaling components

  • Perform immunoprecipitation with PLCB3 antibodies followed by mass spectrometry to identify novel binding partners

• Functional intervention studies:

  • Combine PLCB3 knockdown with antibody detection to validate specificity

  • Use antibodies to confirm PLCB3 depletion in calcium signaling rescue experiments

• Disease model applications:

  • Apply PLCB3 antibodies in cystic fibrosis models to study calcium-dependent IL-8 expression

  • As shown in research, PLCB3 is implicated in extracellular nucleotide-dependent calcium signaling in bronchial epithelial cells exposed to Pseudomonas aeruginosa

What are the considerations for using PLCB3 antibodies in multiplex immunoassays?

When incorporating PLCB3 antibodies in multiplex immunoassays:

• Antibody compatibility:

  • Test for cross-reactivity with other primary antibodies in the panel

  • Ensure host species compatibility to avoid secondary antibody cross-reactivity

  • Consider using directly conjugated antibodies for complex panels

• Epitope accessibility:

  • Verify that multiplexed staining protocols don't interfere with PLCB3 epitope detection

  • Optimize antigen retrieval conditions that work for all antibodies in the panel

• Signal optimization:

  • Adjust dilutions to achieve balanced signal intensities across all targets

  • Consider sequential rather than simultaneous incubation if steric hindrance is an issue

• Validation strategies:

  • Perform single-staining controls alongside multiplex assays

  • Include appropriate blocking steps to minimize non-specific binding

• Phosphorylation status:

  • When including phospho-specific PLCB3 antibodies, ensure sample preparation preserves phosphorylation status of all targets

  • Consider the dynamic range of phosphorylation detection in relation to other targets